For decades, fatty liver disease, specifically metabolic dysfunction-associated steatotic liver disease (MASLD), and its more severe inflammatory form, metabolic dysfunction-associated…
Read More
Pens to Pills: The Transformative Era of Oral GLP-1 Receptor Agonists in Drug Discovery and Patient Care
The pharmaceutical landscape for metabolic diseases has reached a pivotal inflection point, marked by the recent approval of the first…
Read More
Boehringer Ingelheim eyes MASH as the next front for survodutide, a GLP-1/glucagon receptor dual agonist
For decades, metabolic dysfunction-associated steatohepatitis (MASH), a more serious inflammatory form of fatty liver disease, remained a largely overlooked condition,…
Read More
Boehringer Ingelheim Eyes MASH as the Next Front for Survodutide, a GLP-1/Glucagon Receptor Dual Agonist
For decades, fatty liver disease, specifically its more severe inflammatory manifestation known as metabolic dysfunction-associated steatohepatitis (MASH), remained a significant…
Read More
Boehringer Ingelheim eyes MASH as the next front for survodutide, a GLP-1/glucagon receptor dual agonist
For decades, fatty liver disease, and its more severe inflammatory progression known as metabolic dysfunction-associated steatohepatitis (MASH), remained largely overlooked…
Read More
Boehringer Ingelheim eyes MASH as the next front for survodutide, a GLP-1/glucagon receptor dual agonist
Neeraja Balachander, who oversees Boehringer Ingelheim’s extensive cardio-renal-metabolic portfolio, articulated the company’s ambitious vision. “We have a program in MASH,…
Read More
Boehringer Ingelheim eyes MASH as the next front for survodutide, a GLP-1/glucagon receptor dual agonist.
For decades, metabolic dysfunction-associated steatohepatitis (MASH), the more severe inflammatory form of fatty liver disease, was a silent epidemic, often…
Read More
The Potential Anticancer Effects of GLP-1 Receptor Agonists: A Promising Frontier, Yet Still Under Intense Scientific Scrutiny
SAN DIEGO – The rapidly expanding therapeutic landscape of glucagon-like peptide-1 (GLP-1) receptor agonists, widely recognized for their transformative impact…
Read More
Bayer Acquires Perfuse Therapeutics for Up to $2.45 Billion to Bolster Ophthalmology Pipeline with Novel Endothelin Receptor Antagonist
Bayer AG is set to significantly expand its presence in the ophthalmology market with the acquisition of Perfuse Therapeutics, a…
Read More
GLP-1 Receptor Agonists and the Emerging Question of Anticancer Effects
The rapidly expanding landscape of drugs designed to mimic glucagon-like peptide-1 (GLP-1), famously exemplified by Ozempic and Wegovy, is increasingly…
Read MoreYOU MAY HAVE MISSED
